Cartherics and TiCARos collaborate to lead advancement of CLIP-CAR technology

Cartherics, a leading biotechnology company specializing in cancer therapies, has announced a collaboration with TiCARos, a cutting-edge CAR-T cell technology company. Under the terms of the agreement, TiCARos will generate CLIP-CAR constructs to be incorporated into Cartherics’ NK cells for assessing their function both in vitro and in vivo. This partnership aims to enhance the efficacy of cancer therapies by combining TiCARos’ innovative CLIP-CAR approach with Cartherics’ allogeneic NK cell platform.

TiCARos is well known for its unique CLIP-CAR technology that modifies the CAR structure to stabilize the immune synapse between immune cells and target tumor cells, resulting in improved efficacy in models. By collaborating with TiCARos, Cartherics hopes to build a leading portfolio of therapeutic products for cancer treatment. The collaboration will focus on developing a CAR-NK product targeting tissue factor (TF) for triple negative breast cancer and other challenging cancers.

Each company has nominated a specific tumor antigen to target with the CARs, with Cartherics focusing on TF and TiCARos targeting CD19. The collaboration aims to accelerate pipeline programs and expand the use of TiCARos’ technology beyond autologous cell therapies. If the research collaboration yields positive results, Cartherics and TiCARos will negotiate a development and commercialization agreement for their CAR-NK therapeutic approach.

Professor Alan Trounson, CEO of Cartherics, believes that combining TiCARos’ CLIP-CAR technology with Cartherics’ allogeneic NK cell platform has the potential to enhance the effectiveness of cancer therapies. By collaborating with innovative companies like TiCARos, Cartherics aims to develop cutting-edge therapeutic products that can help patients fight cancer more effectively.

Overall, this collaboration between two leading companies in the biotechnology industry represents an exciting opportunity to advance our understanding of CAR-T cell therapy and improve its effectiveness in treating cancer.

By Sophia Gonzalez

As a content writer at, I am dedicated to crafting engaging stories that captivate our readers. With a knack for turning complex topics into accessible and compelling narratives, I weave words together to inform and inspire. My passion lies in delivering accurate and thought-provoking content that keeps our audience informed and entertained. From breaking news stories to in-depth features, I strive to bring a fresh perspective to every piece I create. Join me on this journey of exploration and discovery through the power of words at

Leave a Reply